Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

822 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms.
Honda K, Kobayashi M, Okusaka T, Rinaudo JA, Huang Y, Marsh T, Sanada M, Sasajima Y, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Miura N, Kamita M, Sakamoto T, Shoji H, Jung G, Srivastava S, Yamada T. Honda K, et al. Among authors: shoji h. Sci Rep. 2015 Nov 9;5:15921. doi: 10.1038/srep15921. Sci Rep. 2015. PMID: 26549697 Free PMC article.
Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
Sasaki Y, Hamaguchi T, Yamada Y, Takahashi N, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Nagai Y, Taniguchi H, Boku N, Ushijima T, Shimada Y. Sasaki Y, et al. Among authors: shoji h. Asian Pac J Cancer Prev. 2016;17(2):539-43. doi: 10.7314/apjcp.2016.17.2.539. Asian Pac J Cancer Prev. 2016. PMID: 26925640 Free article.
Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients.
Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Tada K, et al. Among authors: shoji h. Cancer Immunol Res. 2016 Jul;4(7):592-9. doi: 10.1158/2326-6066.CIR-15-0298. Epub 2016 Apr 28. Cancer Immunol Res. 2016. PMID: 27197061
A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab.
Takahashi N, Iwasa S, Fukahori M, Sudo K, Sasaki Y, Shoji H, Honma Y, Okita NT, Takashima A, Hamaguchi T, Boku N, Shimada Y, Honda K, Yamada T, Yamada Y. Takahashi N, et al. Among authors: shoji h. Cancer Chemother Pharmacol. 2016 Sep;78(3):567-75. doi: 10.1007/s00280-016-3111-x. Epub 2016 Jul 20. Cancer Chemother Pharmacol. 2016. PMID: 27438067 Clinical Trial.
The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy.
Shoji H, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Heike Y, Hamaguchi T. Shoji H, et al. Oncotarget. 2017 May 30;8(56):95083-95094. doi: 10.18632/oncotarget.18297. eCollection 2017 Nov 10. Oncotarget. 2017. PMID: 29221113 Free PMC article.
822 results